Clinical Imaging
Volume 34, Issue 6 , Pages 448-452, November 2010

Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10

  • Anuradha Saokar

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    • Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
  • ,
  • Michael S. Gee

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    • Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
  • ,
  • Tina Islam

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    • Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    • Corresponding Author InformationCorresponding author. Center for Molecular Imaging Research, Department of Radiology, Division of Abdominal Imaging and Intervention, Boston, MA 02114, USA. Tel.: +1 617 724 4266; fax: +1 617 726 4891.
  • ,
  • Peter R. Mueller

      Affiliations

    • Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
  • ,
  • Mukesh G. Harisinghani

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    • Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

Received 28 August 2009; accepted 28 September 2009. published online 15 January 2010.

Abstract 

Patients with pathologically confirmed lymphoma/leukemia were retrospectively identified from a large single-institution phase III clinical trial with ferumoxtran-10. Five (2.3%) of 220 patients had lymphoid malignancies involving lymph nodes. A subset of patients (n=27) with biopsy-proven nodal metastases from genitourinary or breast cancer was selected as control group. Ferumoxtran-10 enhancement patterns and signal-to-noise ratios of lymph nodes involved by metastases and lymphoid malignancy were assessed. Like nodal metastases, nodes involved by lymphoid malignancies demonstrate persistent high T2*-signal intensity on lymphotropic nanoparticle-enhanced magnetic resonance imaging.

Keywords: Lymphoma, Superparamagnetic iron oxide nanoparticles, Ferumoxtran-10, MRI, Lymphotropic nanoparticle-enhanced MRI

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0899-7071(09)00313-1

doi:10.1016/j.clinimag.2009.09.008

Clinical Imaging
Volume 34, Issue 6 , Pages 448-452, November 2010